{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:29:00Z","timestamp":1793831340381,"version":"4.6.1"},"reference-count":61,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T00:00:00Z","timestamp":1680393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Vancomycin (VCM) and daptomycin (DAP) are standard therapies for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, despite concerns regarding clinical utility and growing resistance. Linezolid (LZD) affords superior tissue penetration to VCM or DAP and has been successfully used as salvage therapy for persistent MRSA bacteremia, indicating its utility as a first-choice drug against MRSA bacteremia. In a systematic review and meta-analysis, we compared the effectiveness and safety of LZD with VCM, teicoplanin (TEIC), or DAP in patients with MRSA bacteremia. We evaluated all-cause mortality as the primary effectiveness outcome, clinical and microbiological cure, hospital length of stay, recurrence, and 90-day readmission rates as secondary effectiveness outcomes, and drug-related adverse effects as primary safety outcomes. We identified 5328 patients across 2 randomized controlled trials (RCTs), 1 pooled analysis of 5 RCTs, 1 subgroup analysis (1 RCT), and 5 case-control and cohort studies (CSs). Primary and secondary effectiveness outcomes were comparable between patients treated with LZD versus VCM, TEIC, or DAP in RCT-based studies and CSs. There was no difference in adverse event incidence between LZD and comparators. These findings suggest that LZD could be a potential first-line drug against MRSA bacteremia as well as VCM or DAP.<\/jats:p>","DOI":"10.3390\/antibiotics12040697","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T03:08:31Z","timestamp":1680491311000},"page":"697","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Effectiveness and Safety of Linezolid Versus Vancomycin, Teicoplanin, or Daptomycin against Methicillin-Resistant Staphylococcus aureus Bacteremia: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"12","author":[{"given":"Hitoshi","family":"Kawasuji","sequence":"first","affiliation":[{"name":"Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Nagaoka","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-2947","authenticated-orcid":false,"given":"Yasuhiro","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, Chiba 274-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kou","family":"Kimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Takegoshi","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makito","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Murai","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Karaushi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Infection Control, International Medical Center, Saitama Medical University School of Medicine, Saitama 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Mitsutake","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Infection Control, International Medical Center, Saitama Medical University School of Medicine, Saitama 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2088-8724","authenticated-orcid":false,"given":"Yoshihiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cmi.2022.03.015","article-title":"Staphylococcus aureus bacteraemia mortality: A systematic review and meta-analysis","volume":"28","author":"Bai","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13054-017-1801-3","article-title":"Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment","volume":"21","author":"Hassoun","year":"2017","journal-title":"Crit. Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10096-007-0272-x","article-title":"Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: The role of empiric antibiotic therapy","volume":"26","author":"Canteras","year":"2007","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jac\/dkh088","article-title":"Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections","volume":"53","author":"Wilcox","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: Pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: Noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MAJ.0000000000000338","article-title":"Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"349","author":"Usery","year":"2015","journal-title":"Am. J. Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"106329","DOI":"10.1016\/j.ijantimicag.2021.106329","article-title":"Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"57","author":"Yeager","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"ii17","DOI":"10.1093\/jac\/dkg248","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7326\/0003-4819-138-2-200301210-00015","article-title":"Linezolid: The first oxazolidinone antimicrobial","volume":"138","author":"Moellering","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/cid\/cix1127","article-title":"Busting the myth of \u201cStatic vs. Cidal\u201d: A systemic literature review","volume":"66","author":"Holtom","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14787210.2.1.51","article-title":"A review of linezolid: The first oxazolidinone antibiotic","volume":"2","author":"Stevens","year":"2004","journal-title":"Expert. Rev. Anti-Infect. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jgar.2020.12.009","article-title":"Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus","volume":"24","author":"Kato","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s40121-021-00456-0","article-title":"Comparative efficacy and safety of vancomycin, linezolid, tedizolid, and daptomycin in treating patients with suspected or proven complicated skin and soft tissue infections: An updated network meta-analysis","volume":"10","author":"Feng","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jinf.2012.08.007","article-title":"Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"65","author":"Park","year":"2012","journal-title":"J. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jac\/dkv368","article-title":"When sepsis persists: A review of MRSA bacteraemia salvage therapy","volume":"71","author":"Kullar","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1128\/AAC.00200-10","article-title":"Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus","volume":"54","author":"Caffrey","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"dlaa114","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): Updated guidelines from the UK","volume":"3","author":"Brown","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/infdis\/jiu554","article-title":"Cytotoxic virulence predicts mortality in nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus","volume":"211","author":"Rose","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1128\/AAC.04765-14","article-title":"Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia","volume":"59","author":"Chong","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0149-2918(03)80118-2","article-title":"Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia","volume":"25","author":"Wunderink","year":"2003","journal-title":"Clin. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1128\/AAC.00520-13","article-title":"Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-associated methicillin-resistant Staphylococcus aureus bacteremia","volume":"58","author":"Yoon","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/cid\/civ444","article-title":"Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients","volume":"61","author":"Britt","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","first-page":"CD008056","article-title":"Linezolid versus vancomycin for skin and soft tissue infections","volume":"12","author":"Yue","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ja.2014.142","article-title":"Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant Staphylococci","volume":"68","author":"Mohammad","year":"2015","journal-title":"J. Antibiot."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.1038\/s41598-018-26277-9","article-title":"Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility","volume":"8","author":"Yang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1093\/ofid\/ofy344","article-title":"Temporal and geographic variation in antimicrobial susceptibility and resistance patterns of enterococci: Results from the SENTRY antimicrobial surveillance program, 1997\u20132016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1086\/504084","article-title":"An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus","volume":"42","author":"Patel","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/CMR.00030-13","article-title":"A current perspective on daptomycin for the clinical microbiologist","volume":"26","author":"Humphries","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.50.4.1581-1585.2006","article-title":"Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin","volume":"50","author":"Sakoulas","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: A review of safety and tolerability","volume":"59","author":"Vinh","year":"2009","journal-title":"J. Infect."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","article-title":"Intrapulmonary pharmacokinetics of linezolid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.37.2.281","article-title":"Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients","volume":"37","author":"Lamer","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1128\/AAC.45.6.1843-1846.2001","article-title":"Pharmacokinetics and tissue penetration of linezolid following multiple oral doses","volume":"45","author":"Gee","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1128\/AAC.46.1.31-33.2002","article-title":"Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers","volume":"46","author":"Wise","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/dkf066","article-title":"Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement","volume":"50","author":"Lovering","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jac\/19.3.359","article-title":"Pharmacokinetics of vancomycin in serum and tissue of patients undergoing open-heart surgery","volume":"19","author":"Daschner","year":"1987","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/jac\/dkf207","article-title":"Linezolid penetration into osteo-articular tissues","volume":"50","author":"Rana","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1128\/AAC.32.9.1320","article-title":"Vancomycin concentrations in infected and noninfected human bone","volume":"32","author":"Graziani","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1128\/AAC.02344-14","article-title":"Penetration of daptomycin into bone and synovial fluid in joint replacement","volume":"58","author":"Montange","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1128\/AAC.46.3.936-937.2002","article-title":"Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections","volume":"46","author":"Villani","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1128\/AAC.44.5.1356-1358.2000","article-title":"Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit","volume":"44","author":"Bruguerolle","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12028-018-0657-y","article-title":"Daptomycin plasma and CSF levels in patients with healthcare-associated meningitis","volume":"31","author":"Piva","year":"2019","journal-title":"Neurocrit. Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1586\/14787210.2015.1077700","article-title":"Bacterial meningitis: An update of new treatment options","volume":"13","author":"Nau","year":"2015","journal-title":"Expert. Rev. Anti-Infect. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1473-3099(07)70094-4","article-title":"FDA issue linezolid warning","volume":"7","author":"Senior","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13756-020-00714-9","article-title":"The global prevalence of Daptomycin, Tigecycline, Quinupristin\/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase\u2013negative staphylococci strains: A systematic review and meta-analysis","volume":"9","author":"Shariati","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijantimicag.2012.12.012","article-title":"Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: A meta-analysis of randomised controlled trials","volume":"41","author":"An","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00228-022-03446-4","article-title":"Linezolid pharmacokinetics: A systematic review for the best clinical practice","volume":"79","author":"Heidari","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kawasuji, H., Tsuji, Y., Ogami, C., Kimoto, K., Ueno, A., Miyajima, Y., Kawago, K., Sakamaki, I., and Yamamoto, Y. (2021). Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients. BMC Pharmacol. Toxicol., 22.","DOI":"10.1186\/s40360-021-00479-w"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Kawasuji, H., Tsuji, Y., Ogami, C., Kaneda, M., Murai, Y., Kimoto, K., Ueno, A., Miyajima, Y., Fukui, Y., and Sakamaki, I. (2021). Initially reduced linezolid dosing regimen to prevent thrombocytopenia in hemodialysis patients. Antibiotics, 10.","DOI":"10.3390\/antibiotics10050496"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Matsumoto, K., Oda, K., Shoji, K., Hanai, Y., Takahashi, Y., Fujii, S., Hamada, Y., Kimura, T., Mayumi, T., and Ueda, T. (2022). Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: A consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030489"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/4\/697\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:08:41Z","timestamp":1760123321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/4\/697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,2]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["antibiotics12040697"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12040697","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,2]]}}}